Senior Operating Partner Nick Loporcaro joins as Board Chairman
Chicago, IL, July 26, 2022 — The Vistria Group announced the appointment of Senior Operating Partner, Nick Loporcaro, as Board Chairman at PANTHERx Rare (“PANTHERx” or “the Company”), a premier rare and orphan disease focused specialty pharmacy. This appointment follows the official close of the Firm’s acquisition of the Company on July 14, 2022, by an investor consortium consisting of The Vistria Group, Nautic Partners and General Atlantic.
“PANTHERx has a patient centric model and provides individuals living with rare conditions the opportunity to care for themselves at home and have a better quality of life” explained Jon Maschmeyer, Senior Partner and Co-Head of Healthcare at The Vistria Group. “Our investment in PANTHERx is an extension of our thematic work in pharma services and is a fit with the investments we have made in CareMetx and BioCare.”
“We are excited to have Nick join as Chairman of the Board of PANTHERx. Nick brings decades of expertise and relationships to the team and will be an instrumental player in amplifying the value creation plan for the Company,” said Natasha Latif, Principal at The Vistria Group.
Prior to joining The Vistria Group, Nick served as the President of McKesson Canada and McKesson’s U.S. Pharma and Specialty Health businesses where he oversaw all business development, sales, distribution and operations. After over a decade, Nick left McKesson to become the CEO of Landmark Health where he played an instrumental role in the company’s sale to UnitedHealth Group (Optum). Now, as Senior Operating Partner in Vistria’s Dallas office, Nick’s knowledge of both providers and payers has brought an instructive roadmap for investing in companies offering solutions that consider all sides of the care spectrum.
“It’s truly an honor to join the PANTHERx team and focus on driving impact and making complex treatments increasingly available to patients in need. We’re looking forward to a robust partnership in the road ahead,” said Nick Loporcaro, Senior Operating Partner at The Vistria Group.
In 2019, PANTHERx became the first rare-disease-certified specialty pharmacy awarded the Distinction in Rare Diseases and Orphan Drugs from the Accreditation Commission for Health Care (ACHC). Licensed in all 50 states, the Company works to transform lives by providing access solutions to people living with rare medical conditions. The acquisition of PANTHERx represents the seventh investment from Vistria Fund IV, a $2.68 billion fund.
About PANTHERx Rare Pharmacy
PANTHERx Rare Pharmacy, The Rare Disease Specialty Pharmacy®, is headquartered in Pittsburgh, Pennsylvania. PANTHERx’s mission is to transform lives by delivering medical breakthroughs, clinical excellence, and access solutions to patients afflicted with rare and devastating conditions. Every day we create ways to Define RxARE®, by developing focused solutions, bold innovations, and novel clinical services associated with the life-transforming therapies that we deliver.
PANTHERx was awarded 2018 Specialty Pharmacy of the Year by the National Association of Specialty Pharmacy as well as by the American Pharmacy Purchasing Alliance. Zitter Health Insights awarded PANTHERx the Specialty Pharmacy Patient Choice Award winner for both 2017 and 2018. As a quadruple-accredited pharmacy, PANTHERx holds accreditations from ACHC, URAC, VIPPS, and CPPA.
About The Vistria Group
The Vistria Group is building a new kind of private investment firm that delivers both financial returns and societal impact. It invests in essential industries like healthcare, education and financial services that deliver value for investors as well as communities, employees, and consumers. The Vistria Group works as a true partner with its portfolio companies, drawing on its deep sector knowledge, operational expertise, unique network, diverse team, and impact orientation to achieve transformational growth. With over $8 billion in AUM, The Vistria Group has delivered attractive returns for its investors while achieving positive outcomes for its portfolio companies, and the lives and livelihoods it supports.
